These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 17204865)
1. Evidence of myeloid differentiation in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene. Tsai DE; Luger SM; Kemner A; Swider C; Goradia A; Tomczak E; DiPatri D; Bagg A; Nowell P; Loren AW; Perl A; Schuster S; Thompson JE; Porter D; Andreadis C; Stadtmauer EA; Goldsteini S; Ghalie R; Carroll M Cancer Biol Ther; 2007 Jan; 6(1):18-21. PubMed ID: 17204865 [TBL] [Abstract][Full Text] [Related]
2. Differentiation syndrome in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene. DiNardo CD; Ky B; Vogl DT; Forfia P; Loren A; Luger S; Mato A; Tsai DE Med Oncol; 2008; 25(3):299-302. PubMed ID: 18181037 [TBL] [Abstract][Full Text] [Related]
3. A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia. Tsai DE; Luger SM; Andreadis C; Vogl DT; Kemner A; Potuzak M; Goradia A; Loren AW; Perl AE; Schuster SJ; Porter DL; Stadtmauer EA; Goldstein SC; Thompson JE; Swider C; Bagg A; Mato AR; Carroll M Clin Cancer Res; 2008 Sep; 14(17):5619-25. PubMed ID: 18765556 [TBL] [Abstract][Full Text] [Related]
4. Induced differentiation of acute myeloid leukemia cells by activation of retinoid X and liver X receptors. Sanchez PV; Glantz ST; Scotland S; Kasner MT; Carroll M Leukemia; 2014 Apr; 28(4):749-60. PubMed ID: 23823656 [TBL] [Abstract][Full Text] [Related]
5. A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML. Welch JS; Niu H; Uy GL; Westervelt P; Abboud CN; Vij R; Stockerl-Goldstein KE; Jacoby M; Pusic I; Schroeder MA; Dipersio JF; Cashen AF Am J Hematol; 2014 Aug; 89(8):E103-8. PubMed ID: 24723466 [TBL] [Abstract][Full Text] [Related]
6. Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor. Altucci L; Rossin A; Hirsch O; Nebbioso A; Vitoux D; Wilhelm E; Guidez F; De Simone M; Schiavone EM; Grimwade D; Zelent A; de Thé H; Gronemeyer H Cancer Res; 2005 Oct; 65(19):8754-65. PubMed ID: 16204045 [TBL] [Abstract][Full Text] [Related]
7. Preventive and Therapeutic Effects of the Retinoid X Receptor Agonist Bexarotene on Tumors. Qi L; Guo Y; Zhang P; Cao X; Luan Y Curr Drug Metab; 2016; 17(2):118-28. PubMed ID: 26806040 [TBL] [Abstract][Full Text] [Related]
9. Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies. Norsworthy KJ; Cho E; Arora J; Kowalski J; Tsai HL; Warlick E; Showel M; Pratz KW; Sutherland LA; Gore SD; Ferguson A; Sakoian S; Greer J; Espinoza-Delgado I; Jones RJ; Matsui WH; Smith BD Leuk Res; 2016 Oct; 49():90-7. PubMed ID: 27619199 [TBL] [Abstract][Full Text] [Related]
10. The influence of bexarotene, a selective agonist of the retinoid receptor X (RXR), and tazarotene, a selective agonist of the retinoid acid receptor (RAR), on bone metabolism in rats. Nowak B; Matuszewska A; Filipiak J; Nikodem A; Merwid-Ląd A; Pieśniewska M; Fereniec-Gołębiewska L; Kwiatkowska J; Szeląg A Adv Med Sci; 2016 Mar; 61(1):85-9. PubMed ID: 26569440 [TBL] [Abstract][Full Text] [Related]
11. Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas. Hamada T; Sugaya M; Tokura Y; Ohtsuka M; Tsuboi R; Nagatani T; Tani M; Setoyama M; Matsushita S; Kawai K; Yonekura K; Yoshida T; Saida T; Iwatsuki K J Dermatol; 2017 Feb; 44(2):135-142. PubMed ID: 27543197 [TBL] [Abstract][Full Text] [Related]
12. Retinoid receptor expression and its correlation to retinoid sensitivity in non-M3 acute myeloid leukemia blast cells. Lehmann S; Paul C; Törmä H Clin Cancer Res; 2001 Feb; 7(2):367-73. PubMed ID: 11234892 [TBL] [Abstract][Full Text] [Related]
13. Novel silicon-containing analogues of the retinoid agonist bexarotene: syntheses and biological effects on human pluripotent stem cells. Bauer JB; Lippert WP; Dörrich S; Tebbe D; Burschka C; Christie VB; Tams DM; Henderson AP; Murray BA; Marder TB; Przyborski SA; Tacke R ChemMedChem; 2011 Aug; 6(8):1509-17. PubMed ID: 21726055 [TBL] [Abstract][Full Text] [Related]
14. Bexarotene: a promising anticancer agent. Qu L; Tang X Cancer Chemother Pharmacol; 2010 Jan; 65(2):201-5. PubMed ID: 19777233 [TBL] [Abstract][Full Text] [Related]
15. Differential effects of bexarotene on intrinsic and extrinsic pathways in TRAIL-induced apoptosis in two myeloid leukemia cell lines. Ying SX; Seal S; Abbassi N; Hockenbery DM; Kiem HP; Li X; Pagel JM; Gopal AK; Deeg HJ Leuk Lymphoma; 2007 May; 48(5):1003-14. PubMed ID: 17487744 [TBL] [Abstract][Full Text] [Related]
16. Effect of bexarotene on differentiation of glioblastoma multiforme compared with ATRA. Heo JC; Jung TH; Lee S; Kim HY; Choi G; Jung M; Jung D; Lee HK; Lee JO; Park JH; Hwang D; Seol HJ; Cho H Clin Exp Metastasis; 2016 Jun; 33(5):417-29. PubMed ID: 26957434 [TBL] [Abstract][Full Text] [Related]
17. The MS Remyelinating Drug Bexarotene (an RXR Agonist) Promotes Induction of Human Tregs and Suppresses Th17 Differentiation Gaunt CM; Rainbow DB; Mackenzie RJ; Jarvis LB; Mousa HS; Cunniffe N; Georgieva Z; Brown JW; Coles AJ; Jones JL Front Immunol; 2021; 12():712241. PubMed ID: 34447379 [TBL] [Abstract][Full Text] [Related]
18. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213 [TBL] [Abstract][Full Text] [Related]
19. Bexarotene via CBP/p300 induces suppression of NF-κB-dependent cell growth and invasion in thyroid cancer. Cras A; Politis B; Balitrand N; Darsin-Bettinger D; Boelle PY; Cassinat B; Toubert ME; Chomienne C Clin Cancer Res; 2012 Jan; 18(2):442-53. PubMed ID: 22142826 [TBL] [Abstract][Full Text] [Related]
20. Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation. van Gils N; Verhagen HJMP; Smit L Exp Hematol; 2017 Aug; 52():12-23. PubMed ID: 28456748 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]